Cargando…

Peroxisome Proliferator-Activated Receptor Beta/Delta Agonist Suppresses Inflammation and Promotes Neovascularization

The effects of peroxisome proliferator-activated receptor (PPAR)β/δ ophthalmic solution were investigated in a rat corneal alkali burn model. After alkali injury, GW501516 (PPARβ/δ agonist) or vehicle ophthalmic solution was topically instilled onto the rat’s cornea twice a day until day 7. Patholog...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tobita, Yutaro, Arima, Takeshi, Nakano, Yuji, Uchiyama, Masaaki, Shimizu, Akira, Takahashi, Hiroshi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7432070/ https://www.ncbi.nlm.nih.gov/pubmed/32722564 http://dx.doi.org/10.3390/ijms21155296

Ejemplares similares

Combination of Peroxisome Proliferator-Activated Receptor (PPAR) Alpha and Gamma Agonists Prevents Corneal Inflammation and Neovascularization in a Rat Alkali Burn Model
por: Nakano, Yuji, et al.
Publicado: (2020)

Effects of Selective Peroxisome Proliferator Activated Receptor Agonists on Corneal Epithelial Wound Healing
por: Tobita, Yutaro, et al.
Publicado: (2021)

Peroxisome proliferator-activated receptor alpha agonist suppresses neovascularization by reducing both vascular endothelial growth factor and angiopoietin-2 in corneal alkali burn
por: Arima, Takeshi, et al.
Publicado: (2017)

Prophylactic Instillation of Hydrogen-Rich Water Decreases Corneal Inflammation and Promotes Wound Healing by Activating Antioxidant Activity in a Rat Alkali Burn Model
por: Kasamatsu, Momoko, et al.
Publicado: (2022)

Disulfiram Ophthalmic Solution Inhibited Macrophage Infiltration by Suppressing Macrophage Pseudopodia Formation in a Rat Corneal Alkali Burn Model
por: Ikebukuro, Toyo, et al.
Publicado: (2023)

PPARα Agonist Suppresses Inflammation after Corneal Alkali Burn by Suppressing Proinflammatory Cytokines, MCP-1, and Nuclear Translocation of NF-κB
por: Nakano, Yuichiro, et al.
Publicado: (2018)

An ophthalmic solution of a peroxisome proliferator-activated receptor gamma agonist prevents corneal inflammation in a rat alkali burn model
por: Uchiyama, Masaaki, et al.
Publicado: (2013)

Cellular and Biophysical Pipeline for the Screening of Peroxisome Proliferator-Activated Receptor Beta/Delta Agonists: Avoiding False Positives
por: Videira, Natália Bernardi, et al.
Publicado: (2018)

Observation of Corneal Wound Healing and Angiogenesis Using Low-Vacuum Scanning Electron Microscopy
por: Arima, Takeshi, et al.
Publicado: (2020)

Gene Doping with Peroxisome-Proliferator-Activated Receptor Beta/Delta Agonists Alters Immunity but Exercise Training Mitigates the Detection of Effects in Blood Samples
por: Sibille, Brigitte, et al.
Publicado: (2021)

Pioglitazone, a Peroxisome Proliferator-Activated Receptor γ Agonist, Suppresses Rat Prostate Carcinogenesis
por: Suzuki, Shugo, et al.
Publicado: (2016)

Suppression of Rat Oral Carcinogenesis by Agonists of Peroxisome Proliferator Activated Receptor γ
por: McCormick, David L., et al.
Publicado: (2015)

Enhanced Hepatocarcinogenicity Due to Agonists of Peroxisome Proliferator-Activated Receptors in Senescent Rats: Role of Peroxisome Proliferation, Cell Proliferation, and Apoptosis
por: Youssef, Jihan, et al.
Publicado: (2002)

Inducible Conditional Vascular-Specific Overexpression of Peroxisome Proliferator-Activated Receptor Beta/Delta Leads to Rapid Cardiac Hypertrophy
por: Wagner, Kay-Dietrich, et al.
Publicado: (2016)

The Renoprotective Actions of Peroxisome Proliferator-Activated Receptors Agonists in Diabetes
por: Thomas, M. C., et al.
Publicado: (2012)

The Agonists of Peroxisome Proliferator-Activated Receptor-γ for Liver Fibrosis
por: Li, Jingjing, et al.
Publicado: (2021)

The selective peroxisome proliferator–activated receptor‐delta agonist seladelpar reverses nonalcoholic steatohepatitis pathology by abrogating lipotoxicity in diabetic obese mice
por: Haczeyni, Fahrettin, et al.
Publicado: (2017)

Treatment of experimental autoimmune uveoretinitis with peroxisome proliferator-activated receptor α agonist fenofibrate
por: Osada, Miho, et al.
Publicado: (2014)

Erratum to “Inducible Conditional Vascular-Specific Overexpression of Peroxisome Proliferator-Activated Receptor Beta/Delta Leads to Rapid Cardiac Hypertrophy”
por: Wagner, Kay-Dietrich, et al.
Publicado: (2018)

Structural Insights into Human Peroxisome Proliferator Activated Receptor Delta (PPAR-Delta) Selective Ligand Binding
por: Batista, Fernanda A. H., et al.
Publicado: (2012)

The Peroxisome Proliferator-Activated Receptor (PPAR) α Agonist Fenofibrate Suppresses Chemically Induced Lung Alveolar Proliferative Lesions in Male Obese Hyperlipidemic Mice
por: Kuno, Toshiya, et al.
Publicado: (2014)

Peroxisome Proliferator-Activated Receptor Agonists: Do They Increase Cardiovascular Risk?
por: Aljada, Ahmad, et al.
Publicado: (2009)

Repurposing Peroxisome Proliferator-Activated Receptor Agonists in Neurological and Psychiatric Disorders
por: Sagheddu, Claudia, et al.
Publicado: (2021)

Peroxisome proliferator-activated receptor γ agonist suppresses mast cell maturation and induces apoptosis
por: Zhang, Yu, et al.
Publicado: (2017)

Selective peroxisome proliferator-activated receptorα modulators (SPPARMα): The next generation of peroxisome proliferator-activated receptor α-agonists
por: Fruchart, Jean-Charles
Publicado: (2013)

Interaction between Calpain 5, Peroxisome proliferator-activated receptor-gamma and Peroxisome proliferator-activated receptor-delta genes: a polygenic approach to obesity
por: Sáez, María E, et al.
Publicado: (2008)

Haplotypes of the porcine peroxisome proliferator-activated receptor delta gene are associated with backfat thickness
por: Meidtner, Karina, et al.
Publicado: (2009)

Synergy between peroxisome proliferator‐activated receptor γ agonist and radiotherapy in cancer
por: Huang, Guodong, et al.
Publicado: (2018)

A role for Peroxisome Proliferator-Activated Receptor Beta in T cell development
por: Mothe-Satney, Isabelle, et al.
Publicado: (2016)

Hepatocellular proliferation in response to agonists of peroxisome proliferator-activated receptor alpha: a role for kupffer cells?
por: Alsarra, Ibrahim A, et al.
Publicado: (2006)

Topical administration of the kappa opioid receptor agonist nalfurafine suppresses corneal neovascularization and inflammation
por: Shokirova, Hurramhon, et al.
Publicado: (2021)

Peroxisome proliferator-activated receptor-γ agonists and diabetes: Current evidence and future perspectives
por: Chiarelli, Francesco, et al.
Publicado: (2008)

Peroxisome proliferator-activated receptor agonists modulate neuropathic pain: a link to chemokines?
por: Freitag, Caroline M., et al.
Publicado: (2014)

Modulation Effect of Peroxisome Proliferator-Activated Receptor Agonists on Lipid Droplet Proteins in Liver
por: Zhu, Yun-Xia, et al.
Publicado: (2016)

Antitumor action of the peroxisome proliferator-activated receptor-γ agonist rosiglitazone in hepatocellular carcinoma
por: BO, QI-FU, et al.
Publicado: (2015)

Peroxisome Proliferator Activated Receptor Agonists Modulate Transposable Element Expression in Brain and Liver
por: Ferguson, Laura B., et al.
Publicado: (2018)

Peroxisome Proliferator-Activated Receptors (PPAR)γ Agonists as Master Modulators of Tumor Tissue
por: Heudobler, Daniel, et al.
Publicado: (2018)

Structural Biology-Based Exploration of Subtype-Selective Agonists for Peroxisome Proliferator-Activated Receptors
por: Miyachi, Hiroyuki
Publicado: (2021)

Peroxisome proliferator-activated receptor gamma and its natural agonists in the treatment of kidney diseases
por: Sharma, Vinesh, et al.
Publicado: (2022)

Different skeletal effects of the peroxisome proliferator activated receptor (PPAR)α agonist fenofibrate and the PPARγ agonist pioglitazone
por: Syversen, Unni, et al.
Publicado: (2009)

Cannot write session to /tmp/vufind_sessions/sess_tg067e3u1ha1m3f35i6r0fdlk6